Reevaluating the amyloid cascade hypothesis
George Perry, PhD, The University of Texas at San Antonio, San Antonio, TX, shares his perspective on the future of the amyloid cascade hypothesis in Alzheimer’s disease. Therapeutic strategies aimed at eliminating amyloid-β are widely investigated, and recently, aducanumab, an amyloid-β-directed monoclonal antibody, received accelerated approval as a treatment for Alzheimer’s disease from the U.S. Food and Drug Administration (FDA). Dr Perry explains that removing amyloid-β might have its risks as the peptide plays an antioxidant role. Genetics show that amyloid-β is important, but it is essential to understand how it is associated with Alzheimer’s disease. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).
-
Category
No comments found